Fig 6.

BP4L-18:1:1 is devoid of adverse effects on cardiovascular function and motor activity and lacks abuse potential. (a) Cardiovascular measurements were taken 1 h after dosing. Twenty-four animals total (12 males; 12 females). Data for each animal are from 20 individual HR and BP (MAP) measurements. Doses 1 and 7 indicate the total number of days dosed. Statistics: repeated measures analysis of variance. (b) Motor measurements were taken 1 h after dosing. Twenty-four animals total (12 males; 12 females). Data for each animal are from 10 replicates using the Ugo Basile Rota-Rod ramping from 5 to 80 rpm. Motor activity was measured using the Stoelting ANY-box automated tracking system. Total activity was measured over 20 min. (c) Schematic representation of the conditioned place paradigm training and dosing schedule (D, drug; V, vehicle). (d) An example of a preference trail map for a single rat. (e) BP4L-18:1:1 (5.8 mmol kg⁻¹) did not lead to place preference in either male (left panel) or female (right panel) rats. In contrast, morphine (5 mg kg⁻¹, s.c.) produced a robust place preference (P<0.0001 vs vehicle and BP4L-18:1:1, and P<0.0001 for morphine pre- and post-conditioning).